1. Home
  2. FAC vs ANIP Comparison

FAC vs ANIP Comparison

Compare FAC & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FAC

Factorial Energy Inc. Class A Common Stock

N/A

Current Price

$9.32

Market Cap

1.7B

Sector

Miscellaneous

ML Signal

N/A

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$82.07

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FAC
ANIP
Founded
N/A
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2025
1999

Fundamental Metrics

Financial Performance
Metric
FAC
ANIP
Price
$9.32
$82.07
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$110.00
AVG Volume (30 Days)
198.1K
293.3K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
419.23
EPS
N/A
1.28
Revenue
N/A
$206,547,000.00
Revenue This Year
N/A
$21.01
Revenue Next Year
N/A
$17.59
P/E Ratio
N/A
$65.45
Revenue Growth
N/A
2.47
52 Week Low
$8.70
$62.61
52 Week High
$15.40
$99.50

Technical Indicators

Market Signals
Indicator
FAC
ANIP
Relative Strength Index (RSI) 25.26 48.53
Support Level $8.70 $77.16
Resistance Level N/A $83.66
Average True Range (ATR) 1.31 2.64
MACD -0.23 -0.08
Stochastic Oscillator 7.91 39.80

Price Performance

Historical Comparison
FAC
ANIP

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Share on Social Networks: